BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8812735)

  • 1. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
    Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
    Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
    Turner CT; Hopwood JJ; Brooks DA
    Mol Genet Metab; 2000 Apr; 69(4):277-85. PubMed ID: 10870845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-replacement therapy in mucopolysaccharidosis I.
    Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
    N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
    Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
    Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
    Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
    Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
    Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
    Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
    Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
    J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
    Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
    Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.